论文部分内容阅读
目的:检测非小细胞肺癌(non-small cell lung cancer patients,NSCLC)患者组织和血浆中RAR-β基因甲基化状态,探讨RAR-β基因甲基化在NSCLC筛查和早期诊断中的临床意义。方法:选择120例NSCLC患者,用巢式甲基化特异性聚合酶链反应(nested methylation-specific PCR,nMSP)检测肺癌组织、癌旁组织和外周血血浆RAR-β基因的甲基化,并对120例正常对照组血浆样品进行RAR-β基因甲基化检测,各组检测结果进行比较。结果:肺癌组织RAR-β基因甲基化率59.2%,高于癌旁组织的17.5%(P<0.001);NSCLC患者血浆样品中RAR-β基因甲基化检测率为27.5%,对照组血浆未检测到RAR-β基因甲基化(P<0.001);肺癌患者血浆样品与癌组织RAR-β基因甲基化检出率有显著相关性(P<0.001);血浆中RAR-β基因的甲基化检出率与NSCLC临床分类、临床分期和病理类型均无明显相关性。结论:利用nMSP法对血浆样本RAR-β基因甲基化的检测可为肺癌的早期筛查和诊断提供有价值的信息。
OBJECTIVE: To detect the methylation status of RAR-β in tissues and plasma of patients with non-small cell lung cancer (NSCLC) and to investigate the clinical significance of methylation of RAR-β in screening and early diagnosis of NSCLC significance. Methods: A total of 120 NSCLC patients were selected. The methylation of RAR-β gene was detected by nested methylation-specific PCR (nMSP) in lung cancer tissues and adjacent tissues. The plasma samples of 120 normal control subjects were tested for methylation of RAR-β gene, and the results of each group were compared. Results: The methylation rate of RAR-β gene was 59.2% in lung cancer tissues, which was 17.5% higher than that in paracancerous tissues (P <0.001). The methylation rate of RAR-β gene in plasma samples of NSCLC patients was 27.5% The methylation of RAR-βgene was not detected (P <0.001). There was a significant correlation between the methylation of RAR-βgene in plasma and lung cancer (P <0.001) Methylation detection rate and NSCLC clinical classification, clinical stage and pathological types were not significantly correlated. CONCLUSIONS: The detection of methylation of RAR-β gene in plasma samples by nMSP can provide valuable information for early screening and diagnosis of lung cancer.